The 44 references in paper S. Ovcharenko I., A. Vizel' A., I. Gamova V., I. Dobrotina S., Sh. Zagidullin Z., V. Kupaev I., N. Nedashkovskaya G., L. Postnikova B., O. Ukhanova P., R. Fassakhov S., R. Khamitov F., С. Овчаренко И., А. Визель А., И. Гамова В., И. Добротина С., Ш. Загидуллин З., В. Купаев И., Н. Недашковская Г., Л. Постникова Б., О. Уханова П., Р. Фассахов С., Р. Хамитов Ф. (2017) “Место фиксированной комбинации будесонид / формотерол в лечении хронической обструктивной болезни легких стабильного течения. Заключение совета экспертов Приволжского федерального округа Российской Федерации // A role of budesonide/formoterol fixed combination in the treatment of stable chronic obstructive pulmonary disease. A conclusion of the Expert Council of the Volga Federal district of Russia” / spz:neicon:pulmonology:y:2017:i:1:p:114-121

1
WHO. COPD Fact Sheet No315. 2009. Available at: www.who.int/mediacentre/factsheets/fs315/en/index.html
(check this in PDF content)
2
WHO. Chronic respiratory diseases. 2010. Available at: http:// www.who.int/respiratory/copd/burden/en/index.html.
(check this in PDF content)
3
Groenewegen K.H., Schols A.M., Wouters E.F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003; 124: 459–467.
(check this in PDF content)
4
Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–36. / Chuchalin A.G., Avdeev S.N., Aysanov Z.R. et al. Federal Clinical Guidelines on Diagnosis and Management of Chronic Obstructive Pulmonary Disease. Pul'monologiya. 2014; 3: 15–36 (in Russian).
(check this in PDF content)
5
From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017. Available at: http:// www.goldcopd.org
(check this in PDF content)
6
Ozol D., Aysan T., Solak Z.A. et al. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir. Med.2005; 99: 1494–1500.
(check this in PDF content)
7
Barnes P.J. In: Stockley R.A., Rennard S.I., Rabe K. et al. Chronic Obstructive Pulmonary Disease. Oxford: Blackwell Publishing; 2007.
(check this in PDF content)
8
Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67: 957–963.
(check this in PDF content)
9
Seemungal T.A., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 1998; 157: 1418–1422.
(check this in PDF content)
10
Wilkinson T.M., Donaldson G.C., Hurst J.R. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2004; 169: 1298–1303.
(check this in PDF content)
11
Kessler R., Stahl E., Vogelmeier C. et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006; 130: 133–142.
(check this in PDF content)
12
Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med.2010; 363: 1128–1138.
(check this in PDF content)
13
Silva S., Paschoal I.A., De Capitani E.M. et al. COPD phenotypes on computed tomography and its correlation with selected lung function variables in severe patients. Int. J. Chron. Obstruct. Pulm. Dis. 2016; 11: 503–513.
(check this in PDF content)
14
From the Diagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma – COPD Overlap Syndrome (ACOS). 2014. Available at: http://www.gold( copd.org/uploads/users/files/AsthmaCOPDOverlap.pdf
(check this in PDF content)
15
From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017. Available at: http:// www.goldcopd.org
(check this in PDF content)
16
Miravitlles M., Anzueto A., Legnani D. et al. Patient's perception of exacerbations of COPD – the PERCEIVE study. Respir. Med.2007; 101: 453–460.
(check this in PDF content)
17
Partridge M.R., Schuermann W., Beckman O. et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.Ther. Adv. Respir. Dis. 2009; 3: 1–11.
(check this in PDF content)
18
Suissa S., Patenaude V., Lapi F. et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68: 1029–1036.
(check this in PDF content)
19
Kew K.M. Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; 3: CD010115.
(check this in PDF content)
20
Malo De Molina R., Mortensen E.M., Restrepo M.I. et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur. Respir. J. 2010; 36: 751–757.
(check this in PDF content)
21
Agusti A., Fabbri L.M. Inhaled steroids in COPD: when should they be used? Lancet Respir. Med. 2014; 2: 869–871.
(check this in PDF content)
22
Calverley P.M. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2004; 1: 121–124.
(check this in PDF content)
23
Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J.2003; 21: 74–81.
(check this in PDF content)
24
Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.Am. J. Repir. Crit. Care Med.2009; 180: 741–750.
(check this in PDF content)
25
Tashkin D.P., Rennard S.I., Martin P. et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008; 68: 1975–2000.
(check this in PDF content)
26
Aaron S.D., Vandemheen K.L., Ferqusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.Ann. Intern. Med.2007; 146: 545–555.
(check this in PDF content)
27
Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD.N. Engl. J. Med.2016; 374: 2222–2234.
(check this in PDF content)
28
Suzuki T., Tada Y., Kawata N. et al. Clinical, physiological, and radiological features of asthma–chronic obstructive pulmonary disease overlap syndrome.Int. J. Chron. Obstruct. Pulm. Dis.2015; 10: 947–954.
(check this in PDF content)
29
Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014; 371: 1285–1294.
(check this in PDF content)
30
Rossi A., Guerriero M., Corrado A. et al. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir. Res. 2014; 15: 77.
(check this in PDF content)
31
Barnes P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2016; 138: 16–27.
(check this in PDF content)
32
D’Armiento J.M., Scharf S.M., Roth M.D. et al. Eosinophil and T cell markers predict functional decline in COPD patients. Respir. Res.2009; 10: 113.
(check this in PDF content)
33
Saha S., Brightling C.E. Eosinophilic airway inflammation in COPD. Int. J. Chron. Obstruct. Pulm.Dis. 2006; 1: 39–47.
(check this in PDF content)
34
Soriano J.B., Visick G.T., Muellerova H. et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005; 128: 2099–2107.
(check this in PDF content)
35
Hospers J.J., Schouten J.P., Weiss S.T. et al. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample.Am. J. Respir. Crit. Care Med.1999; 160: 1869–1874.
(check this in PDF content)
36
Siva R., Green R.H., Briqhtling C.E. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.Eur. Respir. J. 2007; 29: 906–913.
(check this in PDF content)
37
Kaplan A.G. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice.Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 2535–2548.
(check this in PDF content)
38
Barnes N.C., Sharma R., Lettis S. et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur. Respir. J.2016; 47: 1374–1382.
(check this in PDF content)
39
Pascoe S., Locantore N., Dransfield M.D. et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.Lancet Respir. Med. 2015; 3: 435–442.
(check this in PDF content)
40
Siddiqui S.H., Guasconi A., Vestbo J. et al. Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2015; 192: 523–525.
(check this in PDF content)
41
Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β2-agonist efficacy in COPD. Thorax. 2016; 71: 118–125.
(check this in PDF content)
42
Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.Lancet Respir. Med. 2016; 4: 390–398.
(check this in PDF content)
43
Liesker J.J., Bathoorn E., Postma D.S. et al. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD.Respir. Med.2011; 105: 1853–1860.
(check this in PDF content)
44
Lofdahl C.G., Postma D.S., Pride N.B. et al. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. 2007; 29: 1115–1119. Поступила 13.12.16 Received December 13, 2016
(check this in PDF content)